The transferable exclusivity voucher is a costly, complex and untested incentive for new antibiotics. It does not address access to new and old antibiotics, and it does not help with stewardship. We are worried that the European Commission plans to include the voucher in its proposal to review the EU pharmaceutical legislation rather than test better options. We need to urgently address Antimicrobial Resistance through effective incentives.
The article’s leading author is Christine Årdal and it includes the contribution of EPHA’s Rosa Castro.
